NASDAQ:INM

Inmed Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy INM

*Your capital is at risk

$1.59

+0.0700 (+4.61%)

At Close: Jun 03, 2026

Inmed Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.66M and sold 15.54K INM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	1.66M shares
● Sell	15.54K shares
64% Buy Activity Strong Negative Correlation
Buy Signal Medium Confidence May 19, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 19, 2026 Buy	Common Shares	Adar1 Capital Management, Llc 10 Percent Owner	10% Owner	0 Value: $0
May 19, 2026 Buy	Common Shares P-Purchase	Adar1 Capital Management, Llc 10 Percent Owner	10% Owner	68 551 Value: $109.7K
May 19, 2026 Buy	Common Shares P-Purchase	Adar1 Capital Management, Llc 10 Percent Owner	10% Owner	200 000 Value: $312.1K
May 19, 2026 Buy	Common Shares P-Purchase	Adar1 Capital Management, Llc 10 Percent Owner	10% Owner	200 000 Value: $299.8K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Hull Andrew Director	Director	1 750 Value: $2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Adams Eric A President & CEO	CEO / President	35 000 Value: $45.2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Hsu Eric C Sr. Vp, Pre-clinical Res/dev	Officer	13 000 Value: $16.8K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Bathery John Steven Director	Director	1 750 Value: $2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Woudenberg Michael Chief Operating Officer	C-Suite Officer	18 000 Value: $23.2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Jagpal Netta Chief Financial Officer	C-Suite Officer	18 000 Value: $23.2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Klompas Neil A Director	Director	1 750 Value: $2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Lemerond Nicole Director	Director	1 750 Value: $2K
Dec 19, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Johnson Shane Aaron Sr Vp & General Manager	Officer	8 500 Value: $11.0K
Dec 15, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Hsu Eric C Sr. Vp, Pre-clinical Res/dev	Officer	70 Value: $97.9K
Dec 15, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Woudenberg Michael Chief Operating Officer	C-Suite Officer	60 Value: $83.9K
Dec 15, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Adams Eric A President & CEO	CEO / President	250 Value: $349.5K
Dec 15, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Hull Andrew Director	Director	14 Value: $19.6K
Oct 17, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Klompas Neil A Director	Director	3 500 Value: $7K
Oct 14, 2025 Buy	Employee Stock Option (Right to Buy)	Bathery John Steven Director	Director	3 500 Value: $7K
Jan 11, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Hull Andrew Director	Director	2 Value: $6K
Jan 11, 2025 Sell	Employee Stock Option (Expiration) H-ExpireLong	Hull Andrew Director	Director	2 Value: $6K
Dec 20, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Johnson Shane Aaron Sr Vp & General Manager	Officer	1 500 Value: $6K
Dec 20, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Jagpal Netta Chief Financial Officer	C-Suite Officer	3 750 Value: $15.5K
Dec 20, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Lemerond Nicole Director	Director	550 Value: $2K
Dec 20, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Woudenberg Michael Chief Operating Officer	C-Suite Officer	3 750 Value: $15.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INMED PHARMACEUTICALS INC.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it en...

Read Full Profile Here